FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Free Newsletter

About | View Sample | Privacy

Wyeth mulls 5,000 job cuts

Tools

Welcome Wyeth to the layoff parade. The drugmaker is plotting cutbacks, including job cuts that could amount to 10 percent of its 50,000-strong workforce. Because the company is just beginning to hash out the details, no hard numbers are yet available. According to a Wyeth spokesman, the plans will be announced in March.

Wyeth, of course, is facing the same pressures as other pharma companies who've laid off thousands of workers. Take generic competition: The active ingredient in the company's biggest-selling drug, Effexor XR, goes off patent this June, and Sun Pharmaceutical is readying a generic version. Meanwhile, its blockbuster heartburn med Protonix faces a copycat from Teva Pharmaceutical Industries, which is threatening to launch its version even as the companies dispute its patent protection in court. Wyeth and Teva declared a truce till next Thursday while they try to negotiate a settlement.

And in prepping for layoffs, Wyeth joins a veritable roll call of the biggest names in the business. Merck, Pfizer, Bristol-Myers Squibb, Amgen, GlaxoSmithKline--everyone who's anyone is doing it.

- see the Philadelphia Inquirer article
- read about Wyeth and Teva's truce in the Star-Ledger

Related Articles:
Top 8 layoffs of 2007. Report
Pharma layoffs set new record. Report
Wyeth stumbles badly trying to develop new drugs. Report
Wyeth stock down after several setbacks. Report

Bookmark and Share
Get Your FREE FiercePharma Email Newsletter:
Be the first to comment
More stories about Wyeth   Protonix   pharmaceutical layoffs   GlaxoSmithKline   Amgen  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.